Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
NnR2vrkWucy0tZZ7